PHOLIDOTA CHINENSIS ALLEVIATES AZOXYMETHANE/DEXTRAN SULFATE SODIUM-INDUCED COLORECTAL CARCINOGENESIS THROUGH INHIBITION OF TLR4 AND COX-2
DOI:
https://doi.org/10.21010/ajtcam.v12i6.11Keywords:
Pholidota chinensis, Colorectal cancer, Toll-like receptor 4, Cyclooxygenase-2Abstract
Inflammatory bowel disease (IBD) always progresses to colorectal cancer (CRC) which is the second most frequent cause of death by cancer. It is about 2% of population in the lifetime worldwide who at the risk for development of CRC. Oxaliplatin is an effective anticancer drug used for the treatment of advanced CRC, however, it always causes a robust painful neuropathy. Pholidota chinensis is a Chinese folk herbal medicine which was used for treatment of inflammation such as gastroenteritis, duodenal ulcer and bronchitis. In the present study, we examined the role of Pholidota chinensis in inflammation-related colon tumorigenesis which was induced by azoxymethane (AOM)/dextran sulfate sodium (DSS) in mice. We found that Pholidota chinensis can alleviate the colon tumorigenesis. The prevention effects of Pholidota chinensis is similar to oxaliplatin. Specifically, administration of Pholidota chinensis solution suppresses the expression of the proliferating cell nuclear antigen (PCNA), toll-like receptor 4 (TLR4) and cyclooxygenase-2 (COX-2). Our findings suggested that Pholidota chinensis participate in the regulation of colon cancer development through inhibiting the expression of TLR4 and COX-2.Downloads
Published
How to Cite
Issue
Section
License
Copyright: Creative Commons Attribution CC.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.